Latest Business Development News

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.

Island Pharmaceuticals has completed dosing in the Phase 2b cohort of its dengue fever trial, with pharmacokinetic targets met and top-line results expected next month. The company also strengthened its balance sheet by raising $1.94 million through option exercises.

Peako Limited reports a quiet quarter in East Kimberley exploration due to seasonal conditions but successfully completes a significant capital raise, bolstering its cash position to nearly A$2 million.

Careteq Limited reports strong Q3 FY25 progress with near completion of its 1-System platform integration, revenue growth exceeding forecasts, and new strategic partnerships broadening its healthcare footprint.

Stelar Metals advances its exploration and business development efforts in Tier 1 Australian jurisdictions, spotlighting the promising Baratta Copper Project in South Australia.

SG Fleet Group reported robust first-half 2025 results, driven by strong delivery volumes and revenue growth across Australia, New Zealand, and the UK, despite ongoing pressures in the used vehicle market.

BlueScope Steel reported steady revenue of $8.59 billion for the first half of FY2025, maintaining solid earnings despite challenging raw material costs and subdued housing demand. The company’s diversified operations and ongoing capital investments underpin its resilience amid market headwinds.

Microequities Asset Management Group Limited has reported a robust 46.4% increase in profit after tax for the half-year ended December 2024, alongside a record $650 million in Funds Under Management and a raised interim dividend.

LGI Limited reported a 7% rise in revenue and a 3% increase in EBITDA for H1 FY25, driven by expanded power generation capacity and higher landfill gas flows. However, net profit after tax declined by 22%, reflecting ongoing investment and market dynamics.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.